Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIOPE ATRT01 umbrella trial in children with atypical teratoid/rhabdoid tumors
NL-OMON51928Phase 3Not yet recruiting
- Sponsor
- German Society for Pediatric Oncology and Hematology
- Start
- Jun 2022
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in Atypical teratoid rhabdoid tumor (ATRT) and brain neoplasm (4 arms), sponsored by German Society for Pediatric Oncology and Hematology. Primary endpoint: Overall survival at 2 years. Planned start Jun 2022; status: not yet recruiting.
02
Conditions
Atypical teratoid rhabdoid tumor (ATRT)brain neoplasm
Beyond the preview
Go deeper on NL-OMON51928.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51928.